Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.

[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators.

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.

[5] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.

[11] On June 1, 2020, Antibe announced positive results for Otenaproxesul in its final Phase 2 trial – a dose ranging, efficacy study.